Machine-learning algorithm in acute stroke: real-world experience

被引:6
|
作者
Chan, N. [1 ,2 ]
Sibtain, N. [1 ]
Booth, T. [1 ,3 ]
de Souza, P. [4 ]
Bibby, S. [1 ]
Mah, Y. -h. [5 ]
Teo, J. [5 ]
U-King-Im, J. M. [1 ]
机构
[1] Kings Coll Hosp London, Dept Neuroradiol, London, England
[2] Royal London Hosp, Dept Intervent Neuroradiol, Whitechapel Rd, London E1 1BB, England
[3] Kings Coll London, Sch Biomed Engn & Imaging Sci, London, England
[4] Royal London Hosp, Dept Neuroradiol, London, England
[5] Kings Coll Hosp London, Dept Neurol, London, England
关键词
ENDOVASCULAR THROMBECTOMY; ISCHEMIC-STROKE;
D O I
10.1016/j.crad.2022.10.007
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
AIM: To assess the clinical performance of a commercially available machine learning (ML) algorithm in acute stroke.MATERIALS AND METHODS: CT and CT angiography (CTA) studies of 104 consecutive pa-tients (43 females, age range 19-93, median age 62) performed for suspected acute stroke at a single tertiary institution with real-time ML software analysis (RAPIDTM ASPECTS and CTA) were included. Studies were retrospectively reviewed independently by two neuroradiologists in a blinded manner. RESULTS: The cohort included 24 acute infarcts and 16 large vessel occlusions (LVO). RAPIDTM ASPECTS interpretation demonstrated high sensitivity (87.5%) and NPV (87.5%) but very poor specificity (30.9%) and PPV (30.9%) for detection of acute ischaemic parenchymal changes. There was a high percentage of false positives (51.1%). In cases of proven LVO, RAPIDTM ASPECTS showed good correlation with neuroradiologists' blinded independent interpretation, Pearson correlation coefficient = 0.96 (both readers), 0.63 (RAPIDTM vs reader 1), 0.69 (RAPIDTM vs reader 2).RAPIDTM CTA interpretation demonstrated high sensitivity (92.3%), specificity (85.3%), and negative predictive (NPV) (98.5%) with moderate positive predictive value (PPV) (52.2%) for detection of LVO (N=13). False positives accounted for 12.5% of cases, of which 27.3% were attributed to arterial stenosis.CONCLUSION: RAPIDTM CTA was robust and reliable in detection of LVO. Although demon-strating high sensitivity and NPV, RAPIDTM ASPECTS interpretation was associated with a high number of false positives, which decreased clinicians' confidence in the algorithm. However, in cases of proven LVO, RAPIDTM ASPECTS performed well and had good correlation with neu-roradiologists' blinded interpretation. (c) 2022 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:E45 / E51
页数:7
相关论文
共 50 条
  • [31] Real-World Experience with Ofatumumab
    Thomas, K.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 202 - 203
  • [32] Early diagnosis of persons with von Willebrand disease using a machine learning algorithm and real-world data
    Sidonio Jr, Robert F.
    Lu, Anan
    Hale, Sarah
    Caicedo, Jorge
    Bullano, Mike
    Xing, Shan
    [J]. EXPERT REVIEW OF HEMATOLOGY, 2024, 17 (06) : 261 - 268
  • [33] Demonstration of Intelligent HVAC Load Management With Deep Reinforcement Learning: Real-World Experience of Machine Learning in Demand Control
    Du, Yan
    Li, Fangxing
    Kurte, Kuldeep
    Munk, Jeffrey
    Zandi, Helia
    [J]. IEEE POWER & ENERGY MAGAZINE, 2022, 20 (03): : 42 - 53
  • [34] Real-world experience - Reply
    Hutchinson, D
    [J]. CHEMICAL ENGINEERING PROGRESS, 1998, 94 (03) : 8 - 8
  • [35] Real-world experience with ocrelizumab
    Moss, B.
    Parrotta, E.
    Baldassari, L.
    Planchon, S.
    Cohen, J.
    Ontaneda, D.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 780 - 781
  • [36] Real-World Experience with Ocrelizumab
    Moss, Brandon P.
    Utigard, Erica
    Baldassari, Laura E.
    Cohen, Jeffrey A.
    Ontaneda, Daniel D.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 69 - 70
  • [37] Real-world experience of apremilast
    Fremlin, G. A.
    Bedlow, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2017, 177 : 63 - 63
  • [38] Ocrelizumab real-world experience
    Moss, B.
    Utigard, E.
    Baldassari, L.
    Cohen, J.
    Ontaneda, D.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 504 - 505
  • [39] Real-World Experience with Ocrelizumab
    Moss, Brandon
    Parrotta, Erica
    Baldassari, Laura
    Cohen, Jeffrey
    Ontaneda, Daniel
    [J]. NEUROLOGY, 2019, 92 (15)
  • [40] REAL-WORLD EXPERIENCE IN CHEMISTRY
    MELTON, LA
    [J]. SCIENCE, 1994, 266 (5183) : 203 - 204